| 0.41 0 (0%) | 03-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.67 |
1-year : | 0.81 |
| Resists | First : | 0.57 |
Second : | 0.69 |
| Pivot price | 0.56  |
|||
| Supports | First : | 0.38 |
Second : | 0.32 |
| MAs | MA(5) : | 0.55 |
MA(20) : | 0.56 |
| MA(100) : | 1.15 |
MA(250) : | 5.7 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 55.5 |
D(3) : | 49.2 |
| RSI | RSI(14): 47.5 |
|||
| 52-week | High : | 15 | Low : | 0.31 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CLSD ] has closed above bottom band by 40.2%. Bollinger Bands are 74.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 70 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.65 - 0.65 | 0.65 - 0.65 |
| Low: | 0.5 - 0.51 | 0.51 - 0.51 |
| Close: | 0.54 - 0.54 | 0.54 - 0.55 |
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Sun, 22 Mar 2026
If You Invested $1,000 in Clearside Biomed (CLSD) - Stock Titan
Mon, 29 Dec 2025
Clearside Biomedical receives court approval for asset sale bidding procedures - Investing.com
Fri, 05 Dec 2025
Clearside Biomedical Stumbles Through Bankruptcy And Delisting - Finimize
Mon, 01 Dec 2025
News On Clearside Biomedical Inc. (CLSD) Now Under CLSDQ - Moomoo
Tue, 25 Nov 2025
Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process - VisionMonday.com
Tue, 25 Nov 2025
CLSD enters Chapter 11; stock moving from Nasdaq to OTC market - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 4.54e+006 (%) |
| Held by Institutions | 12.8 (%) |
| Shares Short | 90 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.263e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 502.4 % |
| Return on Equity (ttm) | -70.4 % |
| Qtrly Rev. Growth | 3.33e+006 % |
| Gross Profit (p.s.) | -45.03 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 1.63687e+006 |
| Qtrly Earnings Growth | -5.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.1 |
| Dividend | 0 |
| Forward Dividend | 141010 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|